0001209191-23-059774.txt : 20231227
0001209191-23-059774.hdr.sgml : 20231227
20231227161543
ACCESSION NUMBER: 0001209191-23-059774
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231222
FILED AS OF DATE: 20231227
DATE AS OF CHANGE: 20231227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROBERTS EIRY
CENTRAL INDEX KEY: 0001727606
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 231518108
MAIL ADDRESS:
STREET 1: C/O NEUROCRINE BIOSCIENCES, INC.
STREET 2: 12780 EL CAMINO REAL
CITY: SAN DIEO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-22
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001727606
ROBERTS EIRY
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Medical Officer
1
Common Stock
2023-12-22
4
S
0
10000
126.7448
D
19521
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $128.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
18,336 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power
/s/ Darin Lippoldt, Attorney-in-Fact
2023-12-27